Skip to content
Wenlo
Sign in
← Markets

IDEXX Laboratories, Inc.

Jonathan Jay Mazelsky (Executive Chair of the Board) sells IDXX shares

4IDXXFiled Nov 5, 2026, 5:01 PM ET· Period Nov 4, 2026

AI-generated summary

Jonathan Jay Mazelsky, Executive Chair of the Board, Director of IDEXX Laboratories, Inc., exercised 25,140 stock options at an average price of $178.26, valued at $4,481,456.40. They also sold 25,140 shares of Common Stock in open-market transactions at an average price of $703.19, with a total value of $17,678,194.61. Following these transactions, the insider directly held 83,803.302 shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Jonathan Jay Mazelsky · Executive Chair of the Board, Director
DateTransactionSharesPriceValueHeld afterOwnership
Nov 4, 2026M · exercise or conversion of a derivative+25,140$178.26$4,481,456.40108,943.302Direct
Nov 4, 2026S · open-market saleFootnotes F1−1,945$698.26$1,358,120.56106,998.302Direct
Nov 4, 2026S · open-market saleFootnotes F2−4,075$699.33$2,849,760.79102,923.302Direct
Nov 4, 2026S · open-market saleFootnotes F3−1,667$700.33$1,167,441.78101,256.302Direct
Nov 4, 2026S · open-market saleFootnotes F4−4,540$701.36$3,184,158.0696,716.302Direct
Nov 4, 2026S · open-market saleFootnotes F5−2,136$702.21$1,499,922.0694,580.302Direct
Nov 4, 2026S · open-market saleFootnotes F6−3,950$703.45$2,778,623.5590,630.302Direct
Nov 4, 2026S · open-market sale−240$705.59$169,341.6090,390.302Direct
Nov 4, 2026S · open-market saleFootnotes F7−840$707.00$593,880.0089,550.302Direct
Nov 4, 2026S · open-market saleFootnotes F8−1,840$707.84$1,302,433.8887,710.302Direct
Nov 4, 2026S · open-market saleFootnotes F9−1,300$709.00$921,702.4786,410.302Direct
Nov 4, 2026S · open-market saleFootnotes F10−1,501$710.12$1,065,891.1784,909.302Direct
Nov 4, 2026S · open-market saleFootnotes F11−775$711.31$551,264.0984,134.302Direct
Nov 4, 2026S · open-market saleFootnotes F12−331$711.95$235,654.6283,803.302Direct
Nov 4, 2026M · exercise or conversion of a derivativeNon-Qualified Stock Option (right-to-buy)Footnotes F14, F13−25,140——0Direct
Footnotes
  1. F1 Represents the weighted average price of the shares sold ranging from a low of $697.80 to a high of $698.77 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  2. F2 Represents the weighted average price of the shares sold ranging from a low of $698.92 to a high of $699.89 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  3. F3 Represents the weighted average price of the shares sold ranging from a low of $700.00 to a high of $700.80 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  4. F4 Represents the weighted average price of the shares sold ranging from a low of $701.005 to a high of $701.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  5. F5 Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $702.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  6. F6 Represents the weighted average price of the shares sold ranging from a low of $703.04 to a high of $703.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  7. F7 Represents the weighted average price of the shares sold ranging from a low of $706.60 to a high of $707.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  8. F8 Represents the weighted average price of the shares sold ranging from a low of $707.645 to a high of $708.59 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  9. F9 Represents the weighted average price of the shares sold ranging from a low of $708.65 to a high of $709.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  10. F10 Represents the weighted average price of the shares sold ranging from a low of $709.815 to a high of $710.63 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  11. F11 Represents the weighted average price of the shares sold ranging from a low of $710.82 to a high of $711.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  12. F12 Represents the weighted average price of the shares sold ranging from a low of $711.845 to a high of $712.34 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  13. F13 Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2019.
  14. F14 Not applicable.

More IDXX filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.